Immunovia AB (IMMVF)
Immunovia AB operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $0.02, up 0.00% on the session, giving a market capitalisation of $6.1M. On trailing twelve-month figures it carries a trailing P/E of -0.97, a net margin of -7300.3%. Its beta of 2.65 implies it has historically moved more than the broad market.
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.
Immunovia AB is most often compared with the following Healthcare names: